1. Signaling Pathways
  2. Cell Cycle/DNA Damage
  3. CDK
  4. CDK9 Inhibitors

CDK9 Inhibitors

CDK1

CDK2

CDK3

CDK4

CDK5

CDK6

CDK7

CDK8

CDK9

CDK11

CDK12

CDK13

CDK14

CDK16

CDK19

CDC

CLK

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform CDK9 together.

Please try each isoform separately.

CDK9 Specific Inhibitors
Product Name CDK9 CDK1 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK12 CDK13 CDK14 CDK16 CDK19 CDK9 Selectivity Purity
CDK12-IN-E9
CDK9/cyclinT1, IC50: 23.9 nM
 
cdk2/cyclin A, IC50: 932 nM
       
CDK7/Cyclin H/MNAT1, IC50: 1210 nM
            Selective Inhibitor
AZD4573
CDK9, IC50: 4 nM
                          Selective Inhibitor 99.80%
NVP-2
CDK9, IC50: 0.5 nM
                          Selective Inhibitor 99.29%
(+)-BAY-1251152
CDK9/CycT1, IC50: 3 nM
                          Selective Inhibitor 99.66%
PHA-767491 hydrochloride
CDK9, IC50: 34 nM
CDK1, IC50: 250 nM
CDK2, IC50: 240 nM
   
CDK5, IC50: 460 nM
                Selective Inhibitor 99.91%
Atuveciclib
CDK9/CycT1, IC50: 13 nM
CDK9/CycT1(h), IC50: 6 nM
CDK1/CycB(h), IC50: 1100 nM
CDK2/CycE(h), IC50: 1000 nM
CDK3/CycE(h), IC50: 890 nM
 
CDK5/p35(h), IC50: 1600 nM
                Selective Inhibitor 99.20%
LDC000067
CDK9- Cyclin T1, IC50: 44 nM
cdk1-cyclin B1, IC50: 5513 nM
cdk2-cyclin A, IC50: 2441 nM
 
cdk4-cyclin D1, IC50: 9242 nM
                  Selective Inhibitor 98.58%
PROTAC CDK9 Degrader-1
CDK9
                          Selective Inhibitor 99.04%
CDK9-IN-1
CDK9/CycT1, IC50: 39 nM
                          Selective Inhibitor 95.48%
MC180295
CDK9- Cyclin T1, IC50: 5 nM
CDK1-Cyclin B, IC50: 138 nM
cdk2-cyclin A, IC50: 233 nM
cdk2-cyclin E, IC50: 367 nM
CDK3-Cyclin E, IC50: 399 nM
CDK4-Cyclin D, IC50: 112 nM
cdk5-p35, IC50: 159 nM
cdk5-p25, IC50: 186 nM
cdk6-cyclin D3, IC50: 712 nM
CDK7-CycH/MAT1, IC50: 555 nM
            Selective Inhibitor 98.47%
CDK-IN-2
CDK9/cyclinT1, IC50: 8 nM
                          Selective Inhibitor 98.82%
JSH-150
CDK9/cyclinT1, IC50: 1 nM
Cdk1/cyclin B, IC50: 1.34 μM
cdk2/cyclin A, IC50: 2.86 μM
   
Cdk5/p25, IC50: 4.64 μM
 
CDK7/Cyclin H/MNAT1, IC50: 1.72 μM
     
CDK14/Cyclin Y, IC50: 1.68 μM
CDK16/Cyclin Y, IC50: 292 nM
  Selective Inhibitor 98.36%
CDK9-IN-7
CDK9/cyclinT1, IC50: 11 nM
     
CDK4/cyclin D, IC50: 148 nM
 
CDK6/cyclinD, IC50: 145 nM
              Selective Inhibitor 99.80%
CDK9-IN-8
CDK9, IC50: 12 nM
                          Selective Inhibitor 99.06%
FIT-039
CDK9/cyclinT1, IC50: 5.8 μM
                          Selective Inhibitor >98.0%
PHA-767491
CDK9, IC50: 34 nM
CDK1, IC50: 250 nM
CDK2, IC50: 240 nM
   
CDK5, IC50: 460 nM
                Selective Inhibitor
CDK9-IN-9
CDK9, IC50: 1.8 nM
 
CDK2, IC50: 155 nM
                      Selective Inhibitor
PROTAC CDK9 degrader-2
CDK9, IC50: 17 μM (MCF-7 cells)
                          Selective Inhibitor
CDK6/9-IN-1
CDK9, IC50: 39.5 nM
         
CDK6, IC50: 40.5 nM
              Selective Inhibitor
CDK9-IN-11
CDK9
                          Selective Inhibitor
CDK9-IN-10
CDK9
                          Selective Inhibitor
Abemaciclib methanesulfonate
CDK9/cyclinT1, IC50: 57 nM
CDK1/cyclinB1, IC50: 1627 nM
CDK2/cyclinE, IC50: 504 nM
 
Cdk4/cyclin D1, IC50: 2 nM
Cdk5/p25, IC50: 355 nM
CDK5/p35, IC50: 287 nM
CDK6/cyclinD1, IC50: 10 nM
CDK7/Mat1/cyclinH1, IC50: 3910 nM
            Pan Inhibitor 99.95%
THZ531
CDK9, IC50: 10.5 μM
           
CDK7, IC50: 8.5 μM
 
CDK12, IC50: 158 nM
CDK13, IC50: 69 nM
      Pan Inhibitor 99.86%
YKL-5-124 TFA
CDK9, IC50: 3020 nM
 
CDK2, IC50: 1300 nM
       
CDK7, IC50: 53.5 nM
CDK7/Mat1/CycH, IC50: 9.7 nM
            Pan Inhibitor
(R)​-​CR8 trihydrochloride
CDK9/Cyclin T, IC50: 0.18 μM
CDK1/cyclinB1, IC50: 0.09 μM
cdk2/cyclin A, IC50: 0.072 μM
CDK2/cyclinE, IC50: 0.041 μM
   
Cdk5/p25, IC50: 0.11 μM
 
CDK7/cyclin H, IC50: 1.1 μM
            Pan Inhibitor 99.02%
Abemaciclib
CDK9/cyclinT1, IC50: 57 nM
CDK1/cyclinB1, IC50: 1627 nM
CDK2/cyclinE, IC50: 504 nM
 
Cdk4/cyclin D1, IC50: 2 nM
CDK5/p35, IC50: 287 nM
Cdk5/p25, IC50: 355 nM
CDK6/cyclinD1, IC50: 10 nM
CDK7/Mat1/cyclinH1, IC50: 3910 nM
            Pan Inhibitor 99.69%
Dinaciclib
CDK9, IC50: 4 nM
CDK1, IC50: 3 nM
CDK2, IC50: 1 nM
   
CDK5, IC50: 1 nM
                Pan Inhibitor 99.73%
CYC065
CDK9
 
CDK2
                      Pan Inhibitor 99.78%
SNS-032
CDK9, IC50: 4 nM
CDK1, IC50: 480 nM
CDK2, IC50: 38 nM
 
CDK4, IC50: 925 nM
   
CDK7, IC50: 62 nM
            Pan Inhibitor 98.50%
Samuraciclib hydrochloride
CDK9/CycT1, IC50: 1.2 μM
CDK1/cyc A, IC50: 1.8 μM
cdk2/cyclin A, IC50: 578 nM
 
CDK4/Cyc D1, IC50: 49 μM
CDK5/p35NCK, IC50: 9.4 μM
CDK6/cycD1, IC50: 34 μM
CDK7/cyclin H, IC50: 41 nM
            Pan Inhibitor 99.98%
AT7519
CDK9/Cyclin T, IC50: 10 nM
Cdk1/cyclin B, IC50: 210 nM
cdk2/cyclin A, IC50: 47 nM
 
Cdk4/cyclin D1, IC50: 100 nM
CDK5/p35, IC50: 13 nM
cdk6/cyclin D3, IC50: 170 nM
CDK7/Cyclin H/MAT1, IC50: 2400 nM
            Pan Inhibitor 98.15%
AZD-5438
cdk9-cyclin T, IC50: 20 nM
cdk1-cyclin B1, IC50: 16 nM
cdk2-cyclin E, IC50: 6 nM
cdk2-cyclin A, IC50: 45 nM
 
cdk4-cyclin D1, IC50: 449 nM
cdk5-p25, IC50: 14 nM
cdk6-cyclin D3, IC50: 21 nM
cdk7-cyclin H, IC50: 821 nM
            Pan Inhibitor 99.37%
BS-181
CDK9/cycT, IC50: 4.2 μM
CDK1/cycB, IC50: 8.1 μM
CDK2/Cyc E, IC50: 0.88 μM
 
CDK4/Cyc D1, IC50: 33 μM
CDK5/p35NCK, IC50: 3 μM
CDK6/cycD1, IC50: 47 μM
CDK7/CycH/MAT1, IC50: 0.021 μM
            Pan Inhibitor 99.62%
THZ2
CDK9, IC50: 194 nM
CDK1, IC50: 96.9 nM
CDK2, IC50: 222 nM
   
CDK5, IC50: 134 nM
 
CDK7, IC50: 13.9 nM
CDK8, IC50: 6830 nM
          Pan Inhibitor 99.03%
SEL120-34A monohydrochloride
CDK9/cycT, IC50: 1070 nM
             
CDK8/CycC, IC50: 4.4 nM
       
CDK19/CycC, IC50: 10.4 nM
Pan Inhibitor 99.98%
LY2857785
CDK9, IC50: 0.011 μM
           
CDK7, IC50: 0.246 μM
CDK8, IC50: 0.016 μM
          Pan Inhibitor 98.88%
PHA-793887
CDK9/cyclinT1, IC50: 138 nM
Cdk1/cyclin B, IC50: 60 nM
cdk2/cyclin A, IC50: 8 nM
CDK2/cyclinE, IC50: 8 nM
 
Cdk4/cyclin D1, IC50: 62 nM
Cdk5/p25, IC50: 5 nM
 
CDK7/cyclin H, IC50: 10 nM
            Pan Inhibitor 99.95%
CDKI-73
CDK9, IC50: 5.78 nM
CDK1, IC50: 8.17 nM
CDK2, IC50: 3.27 nM
 
CDK4, IC50: 8.18 nM
 
CDK6, IC50: 37.68 nM
CDK7, IC50: 134.26 nM
            Pan Inhibitor 99.58%
Roniciclib
CDK9/cyclinT1, IC50: 5 nM
Cdk1/cyclin B, IC50: 7 nM
CDK2/cyclinE, IC50: 9 nM
 
CDK4/cyclin D, IC50: 11 nM
   
CDK7/Cyclin H/MAT1, IC50: 25 nM
            Pan Inhibitor 98.89%
AT7519 Hydrochloride
CDK9/Cyclin T, IC50: 10 nM
Cdk1/cyclin B, IC50: 210 nM
cdk2/cyclin A, IC50: 47 nM
 
Cdk4/cyclin D1, IC50: 100 nM
CDK5/p35, IC50: 13 nM
cdk6/cyclin D3, IC50: 170 nM
CDK7/Cyclin H/MAT1, IC50: 2400 nM
            Pan Inhibitor 99.99%
Atuveciclib Racemate
CDK9
                          Pan Inhibitor 98.48%
SEL120-34A HCl
CDK9/cycT, IC50: 1070 nM
             
CDK8/CycC, IC50: 4.4 nM
       
CDK19/CycC, IC50: 10.4 nM
Pan Inhibitor 99.80%
Lerociclib dihydrochloride
CDK9/Cyclin T, IC50: 28 nM
CDK1/cyclinB1, IC50: 2.4 μM
cdk2/cyclin A, IC50: 1.5 μM
CDK2/cyclinE, IC50: 3.6 μM
 
Cdk4/cyclin D1, IC50: 1 nM
CDK5/p35, IC50: 832 nM
Cdk5/p25, IC50: 1.2 μM
cdk6/cyclin D3, IC50: 2 nM
CDK7/Cyclin H/MAT1, IC50: 2.4 μM
            Pan Inhibitor 98.45%
Voruciclib hydrochloride
CDK9/CycT1, Ki: 1.68 nM
CDK9/cyc T2, Ki: 0.626 nM
CDK1/cycB, Ki: 5.4 nM
CDK1/cyc A, Ki: 9.1 nM
   
CDK4/Cyc D1, Ki: 3.96 nM
 
CDK6/cycD1, Ki: 2.92 nM
              Pan Inhibitor >98.0%
Riviciclib hydrochloride
CDK9- Cyclin T1, IC50: 0.020 μM
CDK9-cyclin H, IC50: 2.900 μM
CDK1-Cyclin B, IC50: 0.079 μM
cdk2-cyclin A, IC50: 0.224 μM
cdk2-cyclin E, IC50: 2.500 μM
 
cdk4-cyclin D1, IC50: 0.063 μM
 
cdk6-cyclin D3, IC50: 0.396 μM
              Pan 98.33%
(R)​-​CR8
CDK9/Cyclin T, IC50: 0.18 μM
Cdk1/cyclin B, IC50: 0.09 μM
cdk2/cyclin A, IC50: 0.072 μM
CDK2/cyclinE, IC50: 0.041 μM
   
Cdk5/p25, IC50: 0.11 μM
 
CDK7/cyclin H, IC50: 1.1 μM
            Pan Inhibitor >98.0%
SEL120-34A
CDK9/cycT, IC50: 1070 nM
             
CDK8/CycC, IC50: 4.4 nM
       
CDK19/CycC, IC50: 10.4 nM
Pan Inhibitor
AT7519 trifluoroacetate
CDK9/Cyclin T, IC50: 10 nM
Cdk1/cyclin B, IC50: 210 nM
cdk2/cyclin A, IC50: 47 nM
 
Cdk4/cyclin D1, IC50: 100 nM
CDK5/p35, IC50: 13 nM
cdk6/cyclin D3, IC50: 170 nM
CDK7/Cyclin H/MAT1, IC50: 2400 nM
            Pan Inhibitor 98.16%
BS-181 hydrochloride
CDK9/cycT, IC50: 4.2 μM
CDK1/cycB, IC50: 8.1 μM
CDK2/Cyc E, IC50: 0.88 μM
 
CDK4/Cyc D1, IC50: 33 μM
CDK5/p35NCK, IC50: 3 μM
CDK6/cycD1, IC50: 47 μM
CDK7/CycH/MAT1, IC50: 0.021 μM
            Pan Inhibitor
NVP-LCQ195
CDK9/cyclinT1, IC50: 15 nM
Cdk1/cyclin B, IC50: 2 nM
cdk2/cyclin A, IC50: 2 nM
CDK2/cyclinE, IC50: 5 nM
CDK3/Cyclin E, IC50: 42 nM
 
Cdk5/p25, IC50: 1 nM
CDK5/p35, IC50: 1 nM
cdk6/cyclin D3, IC50: 187 nM
CDK7/Cyclin H/MAT1, IC50: 3564 nM
            Pan Inhibitor 99.80%
CDK8/19-IN-1
CDK9, IC50: 270 nM
             
CDK8/CycC, IC50: 0.46 nM
       
CDK19/CycC, IC50: 0.99 nM
Pan Inhibitor
IIIM-290
CDK9/T1, IC50: 94 nM
 
CDK2/A, IC50: 90 nM
                      Pan Inhibitor
Riviciclib
CDK9- Cyclin T1, IC50: 0.020 μM
CDK9-cyclin H, IC50: 2.900 μM
CDK1-Cyclin B, IC50: 0.079 μM
cdk2-cyclin A, IC50: 0.224 μM
cdk2-cyclin E, IC50: 2.540 μM
 
cdk4-cyclin D1, IC50: 0.063 μM
 
cdk6-cyclin D3, IC50: 0.396 μM
              Pan Inhibitor
PROTAC CDK2/9 Degrader-1
CDK9, DC50: 33 nM
 
CDK2, DC50: 62 nM
                      Pan Inhibitor
Lerociclib
CDK9/Cyclin T, IC50: 28 nM
CDK1/cyclinB1, IC50: 2.4 μM
cdk2/cyclin A, IC50: 1.5 μM
CDK2/cyclinE, IC50: 3.6 μM
 
Cdk4/cyclin D1, IC50: 1 nM
CDK5/p35, IC50: 0.832 μM
Cdk5/p25, IC50: 1.2 μM
cdk6/cyclin D3, IC50: 2 nM
CDK7/Cyclin H/MAT1, IC50: 2.4 μM
            Pan Inhibitor
BS-181 dihydrochloride
CDK9, IC50: 4200 nM
 
CDK2, IC50: 880 nM
   
CDK5, IC50: 3000 nM
 
CDK7, IC50: 21 nM
            Pan Inhibitor
Voruciclib
CDK9/cyc T2, Ki: 0.626 nM
CDK9/CycT1, Ki: 1.68 nM
CDK1/cycB, Ki: 5.4 nM
CDK1/cyc A, Ki: 9.1 nM
   
CDK4/Cyc D1, Ki: 3.96 nM
 
CDK6/cycD1, Ki: 2.92 nM
              Pan Inhibitor 99.52%
Bohemine
CDK9/cyclinT1, IC50: 2.7 μM
 
CDK2/cyclinE, IC50: 4.6 μM
cdk2/cyclin A, IC50: 83 μM
                      Pan Inhibitor
(-)-BAY-1251152
CDK9
                          default Inhibitor 99.82%
FN-1501-propionic acid
CDK9
 
CDK2
                      default